Overview

A Trial Evaluating Efficacy and Safety of Prophylactic Administration of Concizumab in Patients With Severe Haemophilia A Without Inhibitors

Status:
Completed

Trial end date:
2020-06-03

Target enrollment:

Participant gender:

Summary

This trial is conducted in Asia, Europe and the United States of America (USA). The aim of the trial is to assess the efficacy of concizumab administered s.c. (subcutaneously, under the skin) once daily in preventing bleeding episodes in patients with severe haemophilia A without inhibitors.

Phase:

Phase 2

Details

Lead Sponsor:

Novo Nordisk A/S

Treatments:

Factor VIII